Bank of America Corp. (NYSE: BAC) and Citigroup Inc. (NYSE: C) both make the list here for upside calls. Citigroup topped a recent upside list from UBS, as their price target for the bank was put at $62, for an implied upside of more than 45% as of now. The consensus price target objective of $50.57 still implies almost 20% upside. On Bank of America, an analyst duel between Meredith Whitney and Dick Bove is the draw. Whitney gave a target of $15 near-term for 25% upside, and higher in the long-term, perhaps up to $20 for closer to 70% upside. Dick Bove’s call is for Bank of America to go back up to $30 in the next two or three years, and that implies upside now of closer to 150%, since the bank shares have pulled back some.
Bona Film Group Ltd. (NASDAQ: BONA) is a name we frankly have never heard of. It is a film distributor in China, so we are throwing out the “you are on your own here” caveat, as we have joked that the only free speech in China comes from CFOs of public Chinese companies that list shares in America. Piper Jaffray started coverage with an Overweight rating and a $6.50 price target, which gives an implied 60% upside to the stock if the firm is correct.
Gulfport Energy Corp. (NASDAQ: GPOR) already was rated Buy at Stern Agee, but the firm raised earnings estimates and raised its price target to $80 on the stock. At $44.87, that implies upside of a whopping 77%, if the firm is accurate. Stern Agee’s note said that near-term catalysts should show that its rally has legs and that its strong liquidity can fund accelerated 2014 development. The firm said that the stock is incredibly undervalued, and the $80 price target only gets Gulfport’s Enterprise/EBITDA multiple in-line with peers.
Halcon Resources Corp. (NYSE: HK) is an independent energy company with a well-healed management team. Wells Fargo gave it a new Outperform rating and a target range of $11 to $12. This implies upside north of 50% at the mid-point of the range. Dan Dicker at TheStreet.com recently told Jim Cramer that he (is long the stock) thinks this can rise to $12 in share price.
MannKind Corp. (NASDAQ: MNKD) could be a huge winner if Merrill Lynch is right. The name was a selected winner on a larger diabetes call from the firm, with a price target recently raised at the end of March to $5.00. The stock was at $3.33 at the time, and that came to upside of 50% on the button. Shares have risen close to 10% since, but there is still much implied upside to an even higher consensus price target from a handful of analysts.
Molycorp Inc. (NYSE: MCP) recently hit a new 52-week low and what appears to be an all-time low, a real feat considering that the stock market is close to an all-time high. The only domestic rare earth materials leader was initiated in new coverage by a firm called D.A. Davidson with a Buy rating and a $7.00 price target on the second day in April. This call itself represented an upside projection of 42.5%. That may sound short of the 50% hurdle, but what was so interesting is that the consensus price target listed by Thomson Reuters is still close to a double at $9.59. We would be cautious in being too aggressive in this high short seller battleground cult stock, but here is the full summary and background for the call.
OvaScience Inc. (OTCBB: OVSC) is another one we have not heard of, other than in name, but JMP Securities sure likes it. This OTC stock focuses on female infertility, and the firm started coverage at Market Outperform and gave it a whopping $20 price target on April 2. The company recently a secured $35 million in a private placement, and it did the offering through several brokerage firms, so we expect more coverage ahead. With a price of about $9 now, JMP sees this one more with more than 100% upside, if it is correct. Again, it is an OTC stock.